Clinical Trial Update: Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, and immunogenicity of a third dose of four formulations of an rMenB + MenACWY meningococcal vaccine in adolescents…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• rMenB + MenACWY combination vaccine (recombinant MenB plus MenACWY meningococcal vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease, Meningococcal Meningitis | Phase 2 | Status: COMPLETED | Results posted: 2014-11-19